The European Commission has launched a structured dialog addressing pharmaceutical supply chain initiatives, aiming to safeguard the security of the European Union’s supply of medicines. A 26 February launch meeting kicked off the structured dialog initiative, which brings together national authorities, patients, nongovernmental organizations working in the health sector and members of the research community.
By coming to a clearer understanding of how global medical supply chains function, the European Health Union and other players in medical supply chains hope to spot where vulnerabilities lie and how they can be addressed.
“The initiative will help to address the resilience of our pharmaceuticals supply chains, in particular to develop production capacity for critical active ingredients, raw materials and medicines in the EU to ensure better preparedness for future health pandemics, in light of the experiences with COVID-19,” wrote the European Health Union in announcing the structured dialog.
The launch meeting was moderated by EC vice president Margaritis Schinas, European commissioner Stella Kyriakides, who heads EC health initiatives, and commissioner Thierry Breton, who oversees the EC’s internal markets. As the structured dialog sessions continue through 2021, the year-end goal is to arrive at policy recommendations that will address identified vulnerabilities…